AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On April 29, 2025,
(GILD) experienced a 2.00% decline in its stock price, with a trading volume of $805 million, ranking 87th in the day's market activity.Gilead Sciences has reached a settlement with the Department of Justice, agreeing to pay $202 million to resolve allegations of kickbacks. The settlement addresses claims that the company used doctor speaker programs as incentives to boost prescriptions for its HIV medications. The majority of the settlement, $177 million, will go to the federal government, with the remaining amount distributed to individual states. The alleged activities occurred between 2011 and 2017.
Analysts have varied opinions on Gilead's future. The average one-year price target for
is $113.94, with projections ranging from $92.00 to $140.00. This suggests a potential upside of 7.36% from the current stock price. Additionally, 30 brokerage firms rate as "Outperform," with an average recommendation of 2.0 on a scale where 1 indicates a Strong Buy and 5 suggests a Sell.In contrast, the GuruFocus GF Value metric for Gilead Sciences is $83.42, indicating a potential downside of 21.4% from the current share price. This metric evaluates the fair trading value based on historical trading multiples, past business growth, and future performance estimates.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.24 2025

Dec.24 2025

Dec.23 2025

Dec.23 2025

Dec.23 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet